Clinical Trials Browser

Completed × anlotinib × Thoracic × Clear all

NCT04691388 2024-12-05

A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor

Phase 2 Completed

NSCLC

NCT04770688 2024-08-15

AUTOMAN

Phase 1/2 Completed

Adenocarcinoma of Lung, Neoplasm Metastasis

NCT04967079 2024-04-23

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT04790409 2023-09-14

Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

Phase 2 Completed

Lung Neoplasms

NCT03743129 2023-06-12

ALTER-L029

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT04507906 2022-06-28

Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung

NCT03736837 2021-03-15

ALTER-L004

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03059797 2019-05-16

Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)

Phase 2 Completed

Small Cell Lung Carcinoma

NCT02388919 2017-09-18

ALTER0303

Phase 2/3 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01924195 2015-10-28

Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms